Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia

European Journal of Haematology

Volumn 85, Issue 4, 2010, Pages 314-320

  Molica, Stefano ^a   Digiesi, Giovanna ^b   Battaglia, Caterina ^a   Cutrona, Giovanna ^c   Antenucci, Anna ^b   Molica, Matteo ^e   Giannarelli, Diana ^b   Sperduti, Isabella ^b   Gentile, Massimo ^d   Morabito, Fortunato ^d   Ferrarini, Manlio ^c  

^a PUGLIESE CIACCIO HOSPITAL   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d Hematology Department   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

chronic lymphocytic leukemia; prognosis; soluble BAFF

Indexed keywords

B CELL ACTIVATING FACTOR; CD38 ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN VARIABLE REGION; PROTEIN KINASE ZAP 70; TUMOR MARKER; ZAP70 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; B CELL ACTIVATING FACTOR BLOOD LEVEL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOGENETICS; DISEASE COURSE; FEMALE; GENDER; GENE DELETION; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; THROMBOCYTE COUNT; TREATMENT OUTCOME; AGE; BIOSYNTHESIS; BLOOD; COHORT ANALYSIS; GENETICS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; MUTATION; PROGNOSIS; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIGENS, CD38; B-CELL ACTIVATING FACTOR; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 77956972088     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01482.x     Document Type: Article

References (24)

1. Moore PA, Belvedere O, Orr A, et al. BlyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999 285 : 260 263.
2. Nardelli B, Belvedere O, Roschke V, et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001 97 : 198 204.
3. Dillon SR, Gross JA, Ansell SM, Novak AJ. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev 2006 5 : 235 246.
4. Novak AJ, Bram RJ, Kay NE, Jelinak DF. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukaemia cells: a mechanism for survival. Blood 2002 100 : 2973 2979.
5. Briones J, Timmerman JM, Hilbert DM, Levy R. BLyS and BLyS receptor expression in non-Hodgkin's lymphomas. Exp Hematol 2002 30 : 135 141.
6. Novak AJ, Darce JR, Arendt BK, et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 2004 103 : 689 694.
7. Novak AJ, Grote DM, Ziesmer SC, et al. Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol 2006 24 : 983 987.
8. Molica S, Digiesi G, Mauro F, et al. Increased serum BAFF (B-cell activating factor of the TNF family) level is a peculiar feature associated with familial chronic lymphocytic leukemia. Leuk Res 2009 33 : 162 165.
9. Planelles L, Castillo-Gutierrez S, Medema JP, et al. APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: prognostic relevance of APRIL for survival. Haematologica 2007 92 : 1284 1285.
10. Bojarska-Junak A, Hus I, Chocholska S, et al. BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: correlation with biological and clinical features. Leuk Res 2009 33 : 1306 1307.
11. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996 87 : 4990 4997.
12. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008 111 : 5446 5456.
13. Cutrona G, Colombo M, Matis S, et al. B lymphocytes in humans express ZAP-70 when activated in vivo. Eur J Immunol 2006 36 : 558 569.
14. Cuneo A, Bigoni R, Rigolin GM, et al. Acquired deletion of the ataxia telengiactasia (ATM) locus in non-Hodgkin's lymphoma: correlation with clinicobiological features. J Clin Oncol 2000 18 : 2607 2614.
15. Molica S. Progression and survival studies in early chronic lymphocytic leukemia. Blood 1991 78 : 895 899.
16. Horton T, Lausen B. On the exact distribution of maximally selected rank statistics. Comput Stat Data Anal 2003 43 : 121 137.
17. Harrell FE Jr., Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996 15 : 361 387.
18. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000 343 : 1910 1916. (Pubitemid 32064784)
19. Moreno C, Montserrat E. New prognostic markers in chronic lymphocytic leukemia. Blood Rev 2008 22 : 211 219.
20. Haiat S, Billard C, Quiney C, et al. Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology 2006 118 : 281 292.
21. Kern C, Cornuel J, Billard C, et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 2004 103 : 679 688.
22. Endo T, Nishio M, Enzler T, et al. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-B pathway. Blood 2007 109 : 703 710.
23. Ansell SM, Novak A, Ziesmer S, et al. Serum BLyS levels after rituximab as initial therapy in patients with follicular grade 1 non-Hodgkin lymphoma. Am J Hematol 2009 84 : 71 3.
24. Ferrer G, Hodgson K, Montserrat E, Moreno C. B cell activator factor and a proliferation-inducing ligand at the cross-road of chronic lymphocytic leukemia and autoimmunity. Leuk Lymphoma 2009 50 : 1075 1082.